Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats

Yasuhiro Masubuchi, Shizuo Narimatsu, Shin Hosokawa, Tokuji Suzuki

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In vitro covalent binding of a chemically reactive metabolite of propranolol to microsomal macromolecules, which is presumed to cause inhibition of its own metabolism in rats, was diminished in liver microsomes from rats pretreated with propranolol. Covalent binding was suppressed by the addition of an antibody against P450BTL, which is a cytochrome P450 (P450) isozyme belonging to the CYP2D subfamily, SDS-PAGE of microsomal proteins after incubation with [3H]propranolol and NADPH indicated that the binding was non-selective but prominent at the molecular mass of approx. 50 kDa, corresponding to those of the P450 protein. The radioactivity peak was markedly but not completely diminished by the addition of reduced glutathione. In a reconstituted system containing P450BTL, NADPH-cytochrome P450 reductase (fp2) and dilauroylphosphatidylcholine, propranolol 4-, 5- and 7-hydroxylase activities decreased time dependently following preincubation with propranolol in the presence of NADPH, indicating time-dependent inactivation of P450BTL. The covalent binding of a reactive metabolite of [3H]propranolol to the proteins was also observed in this system. SDS-PAGE showed that among the three proteins in the reconstituted system, fp2 and P450BTL consisting of two polypeptides with molecular masses of 49 and 32 kDa, the binding was specific for a polypeptide corresponding to the P450 isozyme with a molecular mass of 49 kDa. In addition, the ratio of the amount of covalently bound radiolabelled materials to that of P450BTL which was estimated from each impaired propranolol hydroxylase activity under the same reconstitutional conditions was calculated to be approx. 1.0. These findings indicate that propranolol is a mechanism-based inactivator of a cytochrome P450 isozyme(s) belonging to the CYP2D subfamily.

Original languageEnglish
Pages (from-to)1891-1898
Number of pages8
JournalBiochemical Pharmacology
Volume48
Issue number10
DOIs
Publication statusPublished - Nov 16 1994
Externally publishedYes

Fingerprint

Metabolism
Propranolol
Liver
Rats
Molecular mass
Proteins
Isoenzymes
Metabolites
Mixed Function Oxygenases
NADP
Cytochrome P-450 Enzyme System
Polyacrylamide Gel Electrophoresis
Enzyme inhibition
NADPH-Ferrihemoprotein Reductase
Peptides
Radioactivity
Liver Microsomes
Macromolecules
Glutathione
Antibodies

Keywords

  • cytochrome P450
  • debrisoquine
  • mechanism-based inactivation
  • metabolic activation
  • propranolol 4-hydroxylation
  • reduced glutathione

ASJC Scopus subject areas

  • Pharmacology

Cite this

Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. / Masubuchi, Yasuhiro; Narimatsu, Shizuo; Hosokawa, Shin; Suzuki, Tokuji.

In: Biochemical Pharmacology, Vol. 48, No. 10, 16.11.1994, p. 1891-1898.

Research output: Contribution to journalArticle

Masubuchi, Yasuhiro ; Narimatsu, Shizuo ; Hosokawa, Shin ; Suzuki, Tokuji. / Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. In: Biochemical Pharmacology. 1994 ; Vol. 48, No. 10. pp. 1891-1898.
@article{c9d699ae2c254346b60a63aeae24dfa6,
title = "Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats",
abstract = "In vitro covalent binding of a chemically reactive metabolite of propranolol to microsomal macromolecules, which is presumed to cause inhibition of its own metabolism in rats, was diminished in liver microsomes from rats pretreated with propranolol. Covalent binding was suppressed by the addition of an antibody against P450BTL, which is a cytochrome P450 (P450) isozyme belonging to the CYP2D subfamily, SDS-PAGE of microsomal proteins after incubation with [3H]propranolol and NADPH indicated that the binding was non-selective but prominent at the molecular mass of approx. 50 kDa, corresponding to those of the P450 protein. The radioactivity peak was markedly but not completely diminished by the addition of reduced glutathione. In a reconstituted system containing P450BTL, NADPH-cytochrome P450 reductase (fp2) and dilauroylphosphatidylcholine, propranolol 4-, 5- and 7-hydroxylase activities decreased time dependently following preincubation with propranolol in the presence of NADPH, indicating time-dependent inactivation of P450BTL. The covalent binding of a reactive metabolite of [3H]propranolol to the proteins was also observed in this system. SDS-PAGE showed that among the three proteins in the reconstituted system, fp2 and P450BTL consisting of two polypeptides with molecular masses of 49 and 32 kDa, the binding was specific for a polypeptide corresponding to the P450 isozyme with a molecular mass of 49 kDa. In addition, the ratio of the amount of covalently bound radiolabelled materials to that of P450BTL which was estimated from each impaired propranolol hydroxylase activity under the same reconstitutional conditions was calculated to be approx. 1.0. These findings indicate that propranolol is a mechanism-based inactivator of a cytochrome P450 isozyme(s) belonging to the CYP2D subfamily.",
keywords = "cytochrome P450, debrisoquine, mechanism-based inactivation, metabolic activation, propranolol 4-hydroxylation, reduced glutathione",
author = "Yasuhiro Masubuchi and Shizuo Narimatsu and Shin Hosokawa and Tokuji Suzuki",
year = "1994",
month = "11",
day = "16",
doi = "10.1016/0006-2952(94)90587-8",
language = "English",
volume = "48",
pages = "1891--1898",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats

AU - Masubuchi, Yasuhiro

AU - Narimatsu, Shizuo

AU - Hosokawa, Shin

AU - Suzuki, Tokuji

PY - 1994/11/16

Y1 - 1994/11/16

N2 - In vitro covalent binding of a chemically reactive metabolite of propranolol to microsomal macromolecules, which is presumed to cause inhibition of its own metabolism in rats, was diminished in liver microsomes from rats pretreated with propranolol. Covalent binding was suppressed by the addition of an antibody against P450BTL, which is a cytochrome P450 (P450) isozyme belonging to the CYP2D subfamily, SDS-PAGE of microsomal proteins after incubation with [3H]propranolol and NADPH indicated that the binding was non-selective but prominent at the molecular mass of approx. 50 kDa, corresponding to those of the P450 protein. The radioactivity peak was markedly but not completely diminished by the addition of reduced glutathione. In a reconstituted system containing P450BTL, NADPH-cytochrome P450 reductase (fp2) and dilauroylphosphatidylcholine, propranolol 4-, 5- and 7-hydroxylase activities decreased time dependently following preincubation with propranolol in the presence of NADPH, indicating time-dependent inactivation of P450BTL. The covalent binding of a reactive metabolite of [3H]propranolol to the proteins was also observed in this system. SDS-PAGE showed that among the three proteins in the reconstituted system, fp2 and P450BTL consisting of two polypeptides with molecular masses of 49 and 32 kDa, the binding was specific for a polypeptide corresponding to the P450 isozyme with a molecular mass of 49 kDa. In addition, the ratio of the amount of covalently bound radiolabelled materials to that of P450BTL which was estimated from each impaired propranolol hydroxylase activity under the same reconstitutional conditions was calculated to be approx. 1.0. These findings indicate that propranolol is a mechanism-based inactivator of a cytochrome P450 isozyme(s) belonging to the CYP2D subfamily.

AB - In vitro covalent binding of a chemically reactive metabolite of propranolol to microsomal macromolecules, which is presumed to cause inhibition of its own metabolism in rats, was diminished in liver microsomes from rats pretreated with propranolol. Covalent binding was suppressed by the addition of an antibody against P450BTL, which is a cytochrome P450 (P450) isozyme belonging to the CYP2D subfamily, SDS-PAGE of microsomal proteins after incubation with [3H]propranolol and NADPH indicated that the binding was non-selective but prominent at the molecular mass of approx. 50 kDa, corresponding to those of the P450 protein. The radioactivity peak was markedly but not completely diminished by the addition of reduced glutathione. In a reconstituted system containing P450BTL, NADPH-cytochrome P450 reductase (fp2) and dilauroylphosphatidylcholine, propranolol 4-, 5- and 7-hydroxylase activities decreased time dependently following preincubation with propranolol in the presence of NADPH, indicating time-dependent inactivation of P450BTL. The covalent binding of a reactive metabolite of [3H]propranolol to the proteins was also observed in this system. SDS-PAGE showed that among the three proteins in the reconstituted system, fp2 and P450BTL consisting of two polypeptides with molecular masses of 49 and 32 kDa, the binding was specific for a polypeptide corresponding to the P450 isozyme with a molecular mass of 49 kDa. In addition, the ratio of the amount of covalently bound radiolabelled materials to that of P450BTL which was estimated from each impaired propranolol hydroxylase activity under the same reconstitutional conditions was calculated to be approx. 1.0. These findings indicate that propranolol is a mechanism-based inactivator of a cytochrome P450 isozyme(s) belonging to the CYP2D subfamily.

KW - cytochrome P450

KW - debrisoquine

KW - mechanism-based inactivation

KW - metabolic activation

KW - propranolol 4-hydroxylation

KW - reduced glutathione

UR - http://www.scopus.com/inward/record.url?scp=0027985788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027985788&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(94)90587-8

DO - 10.1016/0006-2952(94)90587-8

M3 - Article

VL - 48

SP - 1891

EP - 1898

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 10

ER -